About ICON
ICON is a publicly listed company based in Dublin (Ireland) founded in 1990. ICON plc is engaged in clinical research and drug development services. It operates on a Professional Services and Managed Services model. The company has 41,900 employees. ICON has completed 18 acquisitions, including Aptiv Solutions, ClinicalRM and Firecrest Clinical. Its website iconplc.com draws about 477 thousand monthly visits. Its Indian entity Icon Clinical Research India Private Limited reported revenue of ₹816 Cr. ICON offers products and services including Clinical Research Solutions, Consulting Services, and Technology Solutions. Its focus areas include Clinical Research, Contract Research Organization, Biotechnology and Drug Development. Its competitors include Medpace, Lambda Therapeutic, JCCT, Dhiti Life Sciences and Diacrin and 3 more.
Company details
ICON plc is recognized as a leading Contract Research Organization (CRO) focused on clinical research and drug development. Services are provided across various sectors including biotechnology, pharmaceuticals, medical devices, and public health. Comprehensive solutions are offered, ranging from early-phase trials to post-marketing support. Specialized therapeutic expertise is delivered in areas such as oncology, cardiovascular, and rare diseases. Innovative technologies and patient-centric approaches are integrated to enhance trial efficiency. Strategic consulting and real-world intelligence are also provided to optimize RD outcomes for clients globally.
- Annual Revenue₹816 Cr
FY 2025 · +28% YoY
- Net Profit₹96.09 Cr
FY 2025 · 12% margin
- EBITDA₹151 Cr
FY 2025 · 19% margin
- Latest Funding Round$4.69M (USD), Grant
Sep 2021
- InvestorsEnterprise Ireland
& 1 more
- Employee Count41,900
- Investments & AcquisitionsAptiv Solutions
& 17 more
Associated legal entities of ICON
ICON operates through Icon Clinical Research India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Icon Clinical Research India Private Limited CIN U74110TN2004PTC054137 | Active | 02 Sep 2004 | Chennai, Tamil Nadu | ₹816 Cr | 3,383 | 3 | View details |
Products & Services of ICON
ICON offers a comprehensive portfolio of products and services, including Clinical Research Solutions, Consulting Services, and Technology Solutions.
Services for drug development are provided by ICON.
Strategic consulting for asset development is offered here.
Technology solutions for clinical research are developed comprehensively.
Apps and channels of ICON
its YouTube channel ICON Plc has 1.93K subscribers and 30 videos.
Videos from ICON
The most watched videos on ICON's YouTube channel, ICON Plc (1.93K subscribers). Click a video to play it here.
More on ICON Plc.
Funding Insights of ICON
- Total Rounds 6
- Last Round Grant — $4.69M
- First Round $789,179
(Sep 2015)
- Investors Count 2
All 6 funding rounds of ICON with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $4.69M | Grant | – | – | |
| Jul 2018 | $225,950 | Grant | – | – | |
| Jan 2018 | $184,163 | Grant | – | – | |
| Jan 2018 | $1.5M | Grant | – | – | |
| Jan 2017 | $657,869 | Grant | – | – | |
| Sep 2015 | $789,179 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in ICON
ICON has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Enterprise Ireland and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Support is provided to Irish manufacturing and service sector businesses. | 1998 | enterprise-ireland.com | Dublin, Ireland | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for ICON
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Icon Clinical Research India Private Limited (ICON)
Icon Clinical Research India Private Limited is the primary company behind ICON. The board of Icon Clinical Research India Private Limited currently have 3 directors; the longest-serving is Bhagyaraj Jaganathan, appointed in 2014. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bhagyaraj Jaganathan DIN 06566759 | Director | 26 Sep 2014 | 12 yrs | Icon Clinical Research India Private Limited |
| Alan Michael Sheehan DIN 07570067 | Director | 18 Jul 2016 | 10 yrs 3 mo | Icon Clinical Research India Private Limited |
| Denzil George Benjamin DIN 09835644 | Director | 26 Dec 2022 | 3 yrs 9 mo | Icon Clinical Research India Private Limited |
People of ICON
1083 people are tracked at ICON (342 in leadership, 741 in team); the tracked headcount is 41,900.
| Name | Role | Group |
|---|---|---|
Sara Romeo | Senior Director, Business Development | Leadership |
Tom O'leary | Chief Information Officer | Leadership |
Joe Cronin | Executive Vice President of Human Resources | Leadership |
Natasja Delgoffe | Senior Director Project Delivery | Leadership |
Adrienne Stoudenmire | Vice President, Global Project Delivery - ICON Biotech | Leadership |
Dr. Neena Nizar | Director Patient Advocacy Strategy - Center Of Rare Disease | Leadership |
Tom Courage | Senior Director Of Business Development | Leadership |
Kim Anderson | Senior Director, Project Delivery | Leadership |
Aleksandra Ziółkowska | Senior Director, Clinical Operations | Leadership |
Shiloh Whitehead | Vice President, Strategic Alliance Management | Leadership |
Saifudheen Mohamed Musthafa | Senior Director, Global Business Operations | Leadership |
Frank Wigger | Vice President, Medical Affairs - Americas | Leadership |
Johan du Toit | Vice President Medical And Scientific Affairs | Leadership |
Ly N. | Senior Medical Director | Leadership |
Paola Moya | Senior Director Of Medical Affairs – Internal Medicine, Americas | Leadership |
Santhosh Mahizhan | Business Partner | Leadership |
Rona Claire Grunspan | Senior Director- Early Clinical Medical Writing | Leadership |
Shannon Griffin | Director Clinical Operations | Leadership |
Agnieszka Szpineta | Senior Director Project Management | Leadership |
Daisy Stevens | Director Of Global Networks And Workplace Infrastructure | Leadership |
1063 more people are available in the full profile.
Complete people profiles for ICON
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ICON
ICON is a publicly listed company on the NASDAQ with ticker symbol ICLR in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 May 1998
- Listed onNASDAQ: ICLR
- Listed entityICON plc
- Exchange sectorCommercial services
- ISINIE0005711209
- Share price$164.34 (-0.04% on the day) · 2026-10-13
- Market capitalisation$12.68B
- Price to earnings298.3
- EPS (diluted, trailing year)$0.55
- Volume (last session)815,111
Financials of ICON
Figures of Icon Clinical Research India Private Limited, the primary company behind ICON, for FY 2025. Revenue was ₹816 Cr (+28% year on year). Net profit was ₹96.09 Cr (12% margin). EBITDA was ₹151 Cr (19% margin). Revenue has grown at a compounded annual rate of +27% over three years and +18% over five years.
- ₹816 CrRevenue · FY 2025 · +28% YoY
- ₹96.09 CrNet profit · 12% margin
- ₹151 CrEBITDA · 19% margin
- ₹1 LakhPaid-up capital
- 3,383Employees (provident fund records)
- +27%Revenue CAGR, 3 years
- +18%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $8.25B | $229.3M | $1.47B |
| 2024 | $8.19B | $739.1M | $1.68B |
| 2023 | $8.12B | $612.3M | $1.69B |
| 2022 | $7.74B | $505.3M | $1.45B |
| 2021 | $5.48B | $153.2M | $953.9M |
Balance sheet, profit and loss, cash flow and ratios of Icon Clinical Research India Private Limited are on its company page.
Detailed financial statements for ICON
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ICON
ICON has strategically engaged in corporate development activities, having acquired 18 companies. Notable acquisitions include Aptiv Solutions, ClinicalRM and Firecrest Clinical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
HumanFirst is integrated into ICON, focusing on digital health solutions. | gohumanfirst.com | San Francisco, United States | 2017 | Feb 2024 | •••• | |
Global full-service CRO services are delivered in over 80 countries. | prahs.com | Raleigh, United States | 1976 | Feb 2021 | $12B | |
Manufacturer of high-precision aluminum die-cast components | medpass.org | Paris, France | 1991 | Jan 2020 | •••• | |
In-home clinical trials are facilitated via integrated nursing services. | symphonyclinicalresearch.com | Vernon Hills, United States | 2003 | Oct 2019 | •••• | |
Provider of research site and patient recruitment services | medinovaresearch.com | Coventry, United Kingdom | 2000 | May 2019 | •••• | |
Molecular diagnostics for oncology applications are provided by MolecularMD. | molecularmd.com | Portland, United States | 2005 | Jan 2019 | •••• | |
Real world evidence and post-approval research services are provided. | mapigroup.com | Lyon, France | 1990 | Jul 2017 | •••• | |
Clinical service provider for vaccines and drugs targeted against infectious diseases | clinicalrm.com | Hinckley, United Kingdom | 1992 | Jun 2016 | •••• | |
Integrated network of clinical research facilities | pmg-research.com | Winston-salem, United States | 1979 | Dec 2015 | •••• | |
Natural anti-dust mite spray for allergy relief is developed. | medimedia.com | Yardley, United States | 1991 | Feb 2015 | $120M |
Complete acquisition details for ICON
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ICON
14 dated milestones of ICON across 34 years, from founding to its latest funding, stage changes and deals.
- Founded ICON is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires MediMedia.
- Funding First funding round of $789K.
- Acquisition Acquires PMG Research.
- Acquisition Acquires ClinicalRM.
- Acquisition Acquires Mapi Group.
- Acquisition Acquires MolecularMD.
- Acquisition Acquires Medinova.
- Acquisition Acquires Symphony Clinical Research.
- Acquisition Acquires MedPass.
- Acquisition Acquires PRA Health Sciences.
- Funding Latest funding round, Grant, of $4.7M.
- Acquisition Acquires HumanFirst.
Competitors of ICON
ICON has 8 listed competitors in our database. They include Medpace, Lambda Therapeutic, JCCT, Dhiti Life Sciences and Diacrin, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| medpace.com | 1992 | Cincinnati, United States | – | – | A range of clinical research services is offered by Medpace. | |
| lambda-cro.com | 1998 | Ahmedabad, India | – | 1,011 | CRO with operations in India, US, Poland, Canada and UK. Winner of Frost & Sullivan 'CRO of the Year' - 2010 | |
| jcct.com | 2005 | Lenexa, United States | – | – | CRO focused on early & end stage clinical trial services | |
| dhitilifesciences.com | 2010 | Delhi, India | – | 21 | Biotechnology company offering in vitro diagnostic products for healthcare sector | |
| diacrin.com | 1989 | Boston, United States | – | – | Educational programs are provided by Diacrin since 1989. | |
| ascadaresearch.org | 2021 | Fullerton, United States | – | 31 | Performs clinical research trials to evaluate investigational drugs and devices. | |
| neomedlabs.com | 2015 | Laval, Canada | – | – | Contract research organisation offering immunology services for vaccines and immunotherapies | |
| tandemclinicalresearch.com | 2016 | Marrero, United States | – | – | Phase I-IV clinical development services are provided by this CRO. |
Detailed competitors of ICON
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ICON
The website of ICON (iconplc.com) receives about 476.9K visits a month and ranks #92,950 among all websites worldwide, #2,665 in Biotechnology and Pharmaceuticals.
- Monthly visits476.9K
▲ 11.4% vs previous month
- Unique visitors140.6K
per month
- Global rank#92,950
among all websites
- Category rank#2,665
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit4.8
- Average visit4 min 50 sec
- DevicesDesktop 67% · Mobile 33%
Websites whose visitors overlap most with ICON. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covance.com | 100% | 20.2K | #688,229 | View details | |
ppdi.com | ppdi.com | 99% | – | #404,899 | – |
| osip.com | 82% | – | – | View details | |
| nicox.com | 82% | 4.8K | #3,757,949 | View details | |
| onyx-pharm.com | 82% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for ICON
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as ICON (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Icon
Complete news archive for ICON
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ICON
ICON was founded in 1990 and raised its 1st funding round 25 years after it was founded.
ICON is headquartered in Dublin, Ireland.
ICON has 41,900 employees.
The primary company behind ICON, Icon Clinical Research India Private Limited, reported revenue of ₹816 Cr for FY 2025, up 28% year on year.
ICON plc is recognized as a leading Contract Research Organization (CRO) focused on clinical research and drug development. Services are provided across various sectors including biotechnology, pharmaceuticals, medical devices, and public health. Comprehensive solutions are offered, ranging from early-phase trials to post-marketing support. Specialized therapeutic expertise is delivered in areas such as oncology, cardiovascular, and rare diseases. Innovative technologies and patient-centric approaches are integrated to enhance trial efficiency. Strategic consulting and real-world intelligence are also provided to optimize RD outcomes for clients globally.
ICON's top competitors include Medpace, Lambda Therapeutic and Dhiti Life Sciences.
ICON offers Clinical Research Solutions, Consulting Services, and Technology Solutions.
Yes, ICON is publicly traded on NASDAQ under the ticker symbol ICLR.
ICON has made 18 acquisitions, including Aptiv Solutions, ClinicalRM, and Firecrest Clinical.
ICON has 2 investors. Key investors include Enterprise Ireland, and European Union.
ICON operates through Icon Clinical Research India Private Limited.
The legal entities of ICON currently have 3 directors, including Bhagyaraj Jaganathan, Denzil George Benjamin, Alan Michael Sheehan.